Catalog No.
Product Name
Application
Product Information
Citations
-
NMDAR Antagonist
Ro 25-6981 hydrochloride is a selective NMDA receptor antagonist that specifically targets the NR2B subunit. This compound exhibits anticonvulsant and anti-parkinsonian properties, making it a valuable tool in neurological research. Ro 25-6981 hydrochloride is particularly relevant for studying mechanisms underlying Parkinson's disease and may contribute to the development of therapeutic strategies for this condition. -
NMDA Receptor Antagonist
LY 274614 is a competitive antagonist of the NMDA receptor, known for its oral bioactivity. This compound is essential for investigating neurological diseases, as it modulates excitatory neurotransmission and can help elucidate mechanisms underlying various neurological conditions. Its application in research supports the study of NMDA receptor-mediated pathways in both in vitro and in vivo models. -
NMDA Receptor Antagonist
MDL 27266 is a potent orally active NMDA receptor antagonist that exhibits neuroprotective properties. This compound serves as a versatile anticonvulsant agent, making it valuable for studies related to seizure disorders and neuroprotection. Its ability to modulate excitatory neurotransmission positions it as a significant research tool in the fields of neurology and pharmacology. -
NMDA Receptor Antagonist
Fluorofelbamate is a potent NMDA receptor antagonist that demonstrates significant anticonvulsant and antiepileptogenic properties. In experimental models, it has shown effectiveness in mitigating self-sustaining status epilepticus (SSSE). This compound is suitable for research applications focused on epilepsy and related neurological conditions. -
NMDA Antagonist
Aptiganel is a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, exhibiting cerebroprotective properties. This compound is primarily utilized in research focused on neuroprotection and stroke models, contributing to the understanding of excitotoxicity and potential therapeutic interventions in neurological disorders. Its mechanism of action may help elucidate pathways involved in neurodegeneration and recovery following ischemic events. -
NMDA Receptor Modulator
NMDA receptor modulator 6 is a potent modulator of the NMDA receptor, an essential component in synaptic transmission and plasticity in the central nervous system. It plays a significant role in addressing neurological disorders by influencing excitatory neurotransmission. Research applications include studying neurodegenerative diseases, cognitive function, and synaptic mechanisms related to NMDA receptor activity. -
NMDA Agonist
Benzylaspartic acid, a derivative of aspartic acid, functions as an NMDA agonist. It exhibits significant antidepressant activity and has been shown to inhibit the development of alcohol-abstinence syndrome in chronic alcohol consumption rat models. This compound is particularly suited for use in research focused on depression and its underlying mechanisms. -
NMDA Receptor Antagonist
(R)-3C4HPG is a selective NMDA receptor antagonist known for its capacity to modulate glutamatergic signaling. This compound exhibits significant biological activity by inhibiting excitatory neurotransmission, making it a valuable tool in neuropharmacological research. It is often employed in studies investigating the pathophysiology of neurological disorders, as well as in the assessment of synaptic plasticity and learning processes. -
NMDA Agonist
NMDA Agonist 1 is a potent NMDA receptor agonist targeting the GluN1/GluN2B complex. It exhibits a Ki value of 96 nM and acts as a partial agonist with an EC50 of 78 nM. This compound is valuable for researching the functional roles of NMDA receptors in neuropharmacology and studying their implications in neurological disorders. -
NMDA Receptor Antagonist
CGP 43487 is an NMDA receptor antagonist that plays a critical role in modulating glutamatergic neurotransmission. This compound has been shown to significantly influence the structural development of the dentate gyrus, making it valuable for research in neurodevelopment and synaptic plasticity. CGP 43487 serves as an important tool for studying therapeutic approaches to neurological disorders associated with NMDA receptor activity. -
NMDA Antagonist
Indantadol is a non-selective NMDA receptor antagonist and MAO inhibitor, demonstrating a non-competitive blockade of [³H]-MK-801 binding with an IC50 of 8.1 μM. It effectively inhibits NMDA-induced dopamine release and exhibits neuroprotective effects, with an ED₅₀ value of 35 μM. Additionally, Indantadol displays significant anticonvulsant properties and mitigates high pain hypersensitivity, making it a valuable reagent for research in neuropharmacology and pain modulation. -
NMDA Inhibitor
Fluorolintane is a potent NMDA receptor inhibitor, with a Ki value of 87.92 nM. This compound effectively disrupts prepulse inhibition in rat models, demonstrating its capacity to modulate synaptic transmission. Additionally, Fluorolintane inhibits NMDA receptor-induced field excitatory postsynaptic potentials in rat hippocampal slices, making it a valuable tool for studying excitatory neurotransmission and its implications in neurological research. -
NMDA Antagonist
ADCI is a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, demonstrating anticonvulsant properties. This compound is widely utilized in research focused on neurological disorders, particularly for its potential to modulate excitatory neurotransmission in various models of epilepsy and neurodegeneration. -
NMDAR Antagonist
Withaphysalin D is a selective antagonist of the N-methyl-D-aspartate receptor (NMDAR) subtype containing GluN2B. Isolated from water lilies, this compound exhibits neuroprotective properties and has been shown to effectively cross the blood-brain barrier. It is valuable for research applications involving neurobiology and the study of excitatory neurotransmission. -
NMDA Receptor Antagonist
5,7-Dichlorokynurenic acid sodium serves as a selective and competitive antagonist at the glycine site of the NMDA receptor, exhibiting a KB of 65 nM. This compound effectively reduces neuron injury induced by NMDA and demonstrates significant anxiolytic-like effects in rodent models, including increased social interaction and open arm exploration. Its application in research supports investigations into the role of glycine in NMDA receptor-mediated synaptic transmission and associated behavioral outcomes. -
AchE Inhibitor/NMDAR Antagonist
Memagal is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 1.16 nM and acts as an N-methyl-D-aspartate receptor (NMDAR) antagonist with a Ki of 4.6 μM. This compound effectively inhibits neurotoxicity triggered by NMDA, demonstrating an IC50 value of 0.28 nM. Memagal serves as a valuable tool for research focused on Alzheimer's disease, providing insights into mechanisms and potential therapeutic approaches. -
Gly/NMDA Receptor Antagonist
CGP-78608 is a highly selective antagonist targeting the glycine-binding site of the NMDA receptor, exhibiting a formidable IC50 of 6 nM. This compound acts as a potentiator of GluN1/GluN3A-mediated glycine currents, with an estimated EC50 in the low nM range (26.3 nM). Additionally, CGP-78608 demonstrates significant anticonvulsant properties, making it a valuable research tool for studies involving excitatory neurotransmission and seizure disorders. -
NMDAR Antagonist
Kaitocephalin acts as an antagonist of the N-methyl-D-aspartate receptor (NMDAR) with Ki values of 7.8 nM for NMDAR, 590 nM for AMPA receptors (AMPAR), and 14,000 nM for kainate receptors (KAR). This compound exhibits neuroprotective effects by inhibiting excitotoxicity, thereby providing a protective mechanism for neurons. Kaitocephalin is valuable for research into neurological diseases, particularly Alzheimer's disease, making it a significant tool for studying excitotoxic pathways and neurodegenerative processes. -
NMDA Receptor Antagonist
CEB-1604 is a selective NMDA receptor antagonist that effectively inhibits NMDA-induced currents in oocytes expressing various NMDA receptor isoforms, including NR1/NR2A, NR1/NR2B, NR1/NR2C, and NR1/NR2D, with IC50 values between 5 to 12 μM. This compound attenuates NMDA-dependent epileptiform discharges in rat cortical wedge preparations and mitigates NMDA's depolarizing effects. CEB-1604 is useful for research into neurological disorders and contributes to the understanding of excitotoxicity-related mechanisms. -
NMDA Antagonist
L-AP5 (L-2-Amino-5-phosphonovaleric acid) is an NMDA receptor antagonist, acting primarily by blocking the NMDA-mediated synaptic transmission. It exhibits weak activity in inhibiting amino acid uptake and synaptic transmission, making it a useful tool in neuropharmacological research. L-AP5 is commonly employed to investigate the roles of NMDA receptors in various neurological processes and disorders, providing insights into excitotoxicity and synaptic plasticity. -
NMDA Receptor Antagonis
GPI-3000 is an NMDA receptor antagonist that demonstrates neuroprotective effects and has the potential to ameliorate metabolic injury. This compound is relevant for research applications focused on metabolic and neurological diseases, providing insights into therapeutic strategies for these conditions. -
NMDAR Modulator
Rapastinel acetate is a modulator of the N-methyl-D-aspartate (NMDA) receptor, exhibiting potent and long-acting antidepressant effects. It enhances long-term potentiation (LTP) of synaptic transmission by transiently increasing NMDA receptor-mediated currents in hippocampal and medial prefrontal cortex pyramidal neurons. Notably, Rapastinel acetate enhances NMDA receptor currents at low concentrations while decreasing them at higher concentrations, reflecting its unique interaction with distinct sites on the NMDA receptor complex. This modulation is associated with a reduced affinity to intracellular calcium inactivation sites, providing insights into its mechanism for augmenting NMDA receptor conductance. -
NMDA Receptor Antagonist
Ro 8-4304 is a non-competitive antagonist of the NMDA receptor, exhibiting voltage-independent and state-dependent inhibition. This compound effectively inhibits NMDA-induced currents with IC50 values of 2.3 μM at 10 μM and 0.36 μM at 100 μM concentrations. Ro 8-4304 is a valuable tool for investigating the role of NMDA receptors in neuropharmacology and related research applications. -
NMDA Antagonist
Neramexane mesylate is a potent antagonist of N-methyl-D-aspartate (NMDA) receptors and α9α10 cholinergic nicotinic receptors. This compound demonstrates significant neuroprotective effects and has been investigated for its potential to alleviate symptoms of moderate to severe tinnitus. Its unique mechanism makes it a valuable tool in neurological research, particularly in studies focusing on auditory disorders and neuroprotection. -
NMDAR Antagonist
NMDA receptor antagonist 5 is a potent antagonist of the NMDA receptor, exhibiting brain permeability and non-toxicity. This compound is particularly useful for investigating neurological disorders and studying synaptic transmission and plasticity. Its ability to modulate NMDA receptor activity makes it a valuable tool for researchers focusing on excitatory neurotransmission and related pathologies. -
L-HCA Antagonist, NMDA Antagonist
(2R,3S)-Chlorpheg is a weak antagonist of L-homocysteic acid (L-HCA) and acts on NMDA receptors. It exhibits inhibitory effects on L-HCA-induced depolarization, making it useful for studying excitatory neurotransmission. Additionally, its role as an NMDA antagonist provides insights into the modulation of synaptic plasticity and various neurological conditions. This compound is valuable for researchers investigating glutamate receptor signaling and related pathways. -
NMDA Receptor Antagonist
Conantokin G is a 17-amino-acid peptide that acts as a potent and selective competitive antagonist of N-methyl-D-aspartate (NMDA) receptors. It effectively inhibits NMDA-evoked currents in murine cortical neurons with an IC50 value of 480 nM. This compound exhibits neuroprotective properties, making it valuable for research in neurobiology and the study of excitotoxicity. -
NMDA Antagonist
DL-AP7 is a competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, playing a significant role as an anticonvulsant. It effectively blocks NMDA-induced convulsions and is utilized in research to explore its effects on learning and memory, particularly in passive avoidance tasks in murine models. This compound serves as a valuable tool for studying neurological conditions and the underlying mechanisms of synaptic plasticity. -
NMDA Receptor Channel Blocker
NMDAR blocker 1 is an NMDA receptor channel blocker with an IC50 of 5.0 μM, characterized by rapid on-off kinetics and strong voltage dependence, without competing with glutamate or glycine. This reagent effectively prevents glutamate/NMDA-induced intracellular Ca2+ overload and modulates the glutamate-nitric oxide-cGMP signaling pathway. NMDAR blocker 1 has been demonstrated to impede excitotoxic neurodegeneration in cultured cerebellar and hippocampal neurons, as well as mitigate excitotoxic effects in a mouse model of hyperammonemia-induced toxicity. It serves as a valuable tool for research into neurodegenerative diseases. -
NMDA Receptor Antagonist
Ro 8-4304 hydrochloride is a selective antagonist targeting the NMDA receptor, specifically inhibiting the NR2B subunit. This compound exhibits non-competitive and voltage-independent antagonistic properties. It is utilized in research applications related to neuropharmacology and studies of synaptic plasticity, providing insights into mechanisms underlying neurological disorders. -
NMDAR Inhibitor
AChE-IN-53 is a potent inhibitor of the NMDA receptor (NMDAR), which plays a key role in mediating excitatory synaptic transmission and is implicated in various neurological disorders. This compound exhibits significant neuroprotective effects and has shown potential in behavioral research applications related to cognitive decline and neurodegenerative conditions. AChE-IN-53 can be utilized to explore therapeutic strategies targeting NMDAR dysregulation in various models of neural injury and disease. -
GluN2B-NMDAR Positive Allosteric Modulator
GluN2B-NMDAR Allosteric Modulator 1 is a selective positive allosteric modulator of the GluN2B subunit of the NMDA receptor. It enhances glutamate- and aspartate-induced GluN2B-NMDAR-mediated currents, exhibiting EC50 values of 43.7 nM and 18 nM, respectively. This compound demonstrates significant potential in reversing anxiety-like behaviors and cognitive impairments in murine models. It serves as a valuable tool for researching neurological disorders, particularly those related to anxiety. -
NMDA-Receptor Antagonist
LY 233053 is a potent competitive antagonist of the NMDA receptor. It exhibits significant anticonvulsant and antiepileptic properties, making it valuable for research in neuronal excitability and seizure-related disorders. This compound is suitable for studies investigating synaptic transmission, neuroprotection, and the underlying mechanisms of various neurological conditions. -
NMDA Antagonist
Traxoprodil mesylate is a potent and selective NMDA receptor antagonist, exhibiting protective effects on hippocampal neurons with an IC50 of 10 nM. This compound is primarily utilized in neuropharmacological research to investigate mechanisms of neuroprotection and the modulation of excitatory neurotransmission. Its specific action makes it a valuable tool for studying various neurological disorders linked to NMDA receptor activity. -
NMDA antagonist
Indantadol hydrochloride is a potent, non-selective NMDA antagonist that also exhibits monoamine oxidase (MAO) inhibitory activity. It effectively inhibits the binding of [³H]-MK-801 to NMDA receptors in a non-competitive manner, with an IC50 of 8.1 μM, and completely abolishes NMDA-induced dopamine release. Additionally, Indantadol hydrochloride demonstrates neuroprotective properties with an ED₅₀ of 35 μM, and displays valuable anticonvulsant and analgesic effects, making it relevant for studies in pain hypersensitivity and seizure disorders. -
NMDA Receptor Antagonist
LY 233536 is a competitive antagonist of the NMDA receptor, acting to inhibit excitatory neurotransmission in the central nervous system. This compound is primarily used in neuroscience research to explore the role of NMDA receptors in synaptic plasticity, neurodegenerative diseases, and pain signaling mechanisms. Its efficacy in modulating receptor activity makes it valuable for investigating various neurological conditions and potential therapeutic strategies. -
NMDA Receptor Inhibitor
NMDA-IN-2 is a selective NMDA receptor 2B subtype inhibitor derived from Procaine. It demonstrates potent inhibitory effects on NMDA receptor activity, making it valuable for studying synaptic transmission and neurotoxicity. This compound has applications in researching neurological disorders and may aid in the development of therapeutic strategies for conditions associated with NMDA receptor dysregulation. -
Positive Allosteric Modulator of NMDAR
SGE-301 is a positive allosteric modulator of the N-methyl-D-aspartate receptor (NMDAR). It effectively restores NMDAR density and normalizes long-term potentiation, making it a valuable tool in the study of neurological disorders. SGE-301 is particularly useful for researchers investigating the role of NMDAR in synaptic plasticity and neurophysiology. -
NMDA Receptor Agonist
trans-ACBD (trans-1-Aminocyclobutane-1,3-dicarboxylic acid) is a potent and selective agonist of the NMDA receptor, primarily targeting glutamatergic neurotransmission. Its ability to modulate NMDA receptor activity makes trans-ACBD a valuable tool in the study of neurobiology, synaptic plasticity, and related disorders. This compound is suitable for diverse research applications involving excitatory neurotransmission pathways. -
NMDA Receptor Antagonist
Neramexane is an oral N-methyl-D-aspartate (NMDA) receptor antagonist with potential neuroprotective properties. It has been investigated for its role in addressing various central nervous system disorders, including Alzheimer's disease, as well as the treatment of drug and alcohol dependence and pain management. This compound is valuable for research into neuroprotection and synaptic modulation. -
NMDA Receptor Blocker
Caged MK801 is a selective, non-competitive, irreversible blocker of the NMDA receptor, targeting the open-channel state. It is designed to release MK801 upon photolysis, providing a tool for precise temporal control in neuronal studies. This compound is compatible with neuropharmacological applications, enabling exploration of synaptic plasticity and neurodegeneration mechanisms. -
NMDAR Modulator
NMDAR Modulator 2 is an NMDA receptor modulator that alters NMDA receptor activity. This compound serves as a valuable tool for investigating psychiatric disorders associated with dysregulated glutamatergic transmission, such as treatment-resistant depression. Its targeted action on NMDA receptors makes it suitable for exploring therapeutic strategies in conditions where glutamate signaling is implicated. -
NMDA Receptor Antagonist
DL-AP5 lithium is a competitive antagonist of the NMDA (N-methyl-D-aspartate) receptor. It demonstrates notable antinociceptive properties, making it a valuable tool in pain research. This compound has been shown to specifically inhibit ion channels in the rabbit retina, providing insights into its potential applications in neuropharmacology and retinal studies. -
NMDA Inhibitor
UBP618 is a non-selective N-methyl-D-aspartate (NMDA) receptor inhibitor. This compound exhibits significant modulation of NMDA receptor activity, making it valuable for studying excitatory neurotransmission and various neurological disorders. UBP618 is utilized in research addressing conditions such as Alzheimer's disease, schizophrenia, and other neurodegenerative disorders, providing insights into synaptic plasticity and neuroprotection mechanisms. -
NMDAR Antagonist
Delucemine hydrochloride is a selective N-methyl-D-aspartate receptor (NMDAR) antagonist, known for its role in modulating glutamatergic signaling. This compound exhibits potential antidepressant properties, making it a valuable tool for researching treatments for mood disorders. Additionally, Delucemine hydrochloride may be utilized to explore the underlying mechanisms of NMDAR-related neuropsychiatric conditions. -
NMDA Receptor Modulator
NMDA Receptor Modulator 8 is an NMDA receptor modulator that exhibits 50%-100% potentiation of the NMDA receptor activity at a concentration of 10 μM. This compound can play a significant role in studies related to synaptic plasticity, neuroprotection, and various neurodegenerative diseases. Its modulation of NMDA receptor function makes it a valuable tool for researchers investigating excitatory neurotransmission and associated pathways. -
NMDAR Antagonist
NMDAR antagonist 4 is a specific antagonist of the NMDA receptor, targeting the glycine site with a binding affinity characterized by a Ki value exceeding 100 μM. This compound has been utilized in biological research to investigate the role of NMDA receptors in various neurological pathways and disorders. Its utility spans studies on excitotoxicity, synaptic plasticity, and potential therapeutic applications in neurodegenerative diseases. -
NMDA Receptor Antagonist
LY 235959 is a competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. This compound enhances the anticonvulsant effects of various antiepileptic agents, making it valuable in the research of epilepsy and related neurological disorders. Its ability to modulate NMDA receptor activity positions LY 235959 as a critical tool for studying synaptic transmission and excitotoxicity. -
NMDA Antagonist
Etoxadrol is a potent NMDA antagonist, exhibiting high affinity for the N-methyl-D-aspartic acid receptor. It is primarily utilized in anesthetic research to modulate pain mechanisms and examine neuroprotective effects. This compound is of particular interest in studies related to pain management and the exploration of anesthetic protocols. -
P2X Receptor Antagonist
PPADS tetrasodium is a non-selective antagonist of P2X receptors, effectively inhibiting recombinant P2X1, -2, -3, and -5 with IC50 values ranging from 1 to 2.6 μM. Additionally, it shows inhibitory effects on native P2Y2-like receptors (IC50 ~0.9 mM) and recombinant P2Y4 receptors (IC50 ~15 mM). This compound also acts as an inhibitor of the reverse mode of the Na/Ca2+ exchanger in guinea pig airway smooth muscle, making it a valuable tool for research on purinergic signaling and related physiological processes.
